SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Mathijssen Ron H. J.)
 

Search: WFRF:(Mathijssen Ron H. J.) > (2015-2019) > Treatment with subc...

Treatment with subcutaneous and transdermal fentanyl : results from a population pharmacokinetic study in cancer patients

Oosten, Astrid W. (author)
Erasmus MC Canc Inst, Dept Med Oncol, Groene Hilledijk 301, NL-3075 EA Rotterdam, Netherlands.
Abrantes, João A. (author)
Uppsala universitet,Institutionen för farmaceutisk biovetenskap,Univ Coimbra, Fac Pharm, Dept Pharmacol, Coimbra, Portugal.;Univ Coimbra, CNC Ctr Neurosci & Cell Biol, Coimbra, Portugal.
Jönsson, Siv (author)
Uppsala universitet,Institutionen för farmaceutisk biovetenskap
show more...
de Bruijn, Peter (author)
Erasmus MC Canc Inst, Dept Med Oncol, Groene Hilledijk 301, NL-3075 EA Rotterdam, Netherlands.
Kuip, Evelien J. M. (author)
Erasmus MC Canc Inst, Dept Med Oncol, Groene Hilledijk 301, NL-3075 EA Rotterdam, Netherlands.
Falcao, Amilcar (author)
Univ Coimbra, Fac Pharm, Dept Pharmacol, Coimbra, Portugal.;Univ Coimbra, CNC Ctr Neurosci & Cell Biol, Coimbra, Portugal.
van der Rijt, Carin C. D. (author)
Erasmus MC Canc Inst, Dept Med Oncol, Groene Hilledijk 301, NL-3075 EA Rotterdam, Netherlands.;Netherlands Comprehens Canc Org, Utrecht, Netherlands.
Mathijssen, Ron H. J. (author)
Erasmus MC Canc Inst, Dept Med Oncol, Groene Hilledijk 301, NL-3075 EA Rotterdam, Netherlands.
show less...
Erasmus MC Canc Inst, Dept Med Oncol, Groene Hilledijk 301, NL-3075 EA Rotterdam, Netherlands Institutionen för farmaceutisk biovetenskap (creator_code:org_t)
2016-01-14
2016
English.
In: European Journal of Clinical Pharmacology. - : Springer Science and Business Media LLC. - 0031-6970 .- 1432-1041. ; 72:4, s. 459-467
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Transdermal fentanyl is effective for the treatment of moderate to severe cancer-related pain but is unsuitable for fast titration. In this setting, continuous subcutaneous fentanyl may be used. As data on the pharmacokinetics of continuous subcutaneous fentanyl are lacking, we studied the pharmacokinetics of subcutaneous and transdermal fentanyl. Furthermore, we evaluated rotations from the subcutaneous to the transdermal route. Fifty-two patients treated with subcutaneous and/or transdermal fentanyl for moderate to severe cancer-related pain participated. A population pharmacokinetic model was developed and evaluated using non-linear mixed-effects modelling. For rotations from subcutaneous to transdermal fentanyl, a 1:1 dose conversion ratio was used while the subcutaneous infusion was continued for 12 h (with a 50 % tapering after 6 h). A 6-h scheme with 50 % tapering after 3 h was simulated using the final model. A one-compartment model with first-order elimination and separate first-order absorption processes for each route adequately described the data. The estimated apparent clearance of fentanyl was 49.6 L/h; the absorption rate constant for subcutaneous and transdermal fentanyl was 0.0358 and 0.0135 h(-1), respectively. Moderate to large inter-individual and inter-occasion variability was found. Around rotation from subcutaneous to transdermal fentanyl, measured and simulated plasma fentanyl concentrations rose and increasing side effects were observed. We describe the pharmacokinetics of subcutaneous and transdermal fentanyl in one patient cohort and report several findings that are relevant for clinical practice. Further research is warranted to study the optimal scheme for rotations from the subcutaneous to the transdermal route.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmaceutiska vetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmaceutical Sciences (hsv//eng)

Keyword

Fentanyl
Pharmacokinetics
Subcutaneous
Transdermal
NONMEM

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view